替考拉宁在中国成人患者中的群体药动学研究

目的建立中国成年患者的替考拉宁(teicoplanin,TEC)群体药动学(population pharmacokinetics,PPK)模型,考察TEC药动学参数的影响因素。方法前瞻性收集139例革兰阳性球菌感染患者静脉注射TEC后的222份常规监测血药浓度和相关信息,采用一级消除的一室模型进行数据拟合,并应用非线性混合效应模型(nonlinear mixed effect model,NONMEM)程序建立PPK模型。采用Bootstrap、正态预测分布误差法(normalized predictive distribution error,NPDE)进行最终模型评价。利用蒙特卡洛模拟法对给药方案进行优化。结果确定了肌酐清除率(creatinine clearance,CLcr)、白蛋白(albumin,ALB)为影响TEC清除率的主要因素。最终模型为:CL(L·h^-1)=1.24×(CLcr/77)0.564×31/ALB;V(L)=69.2。验证表明,模型稳定、有效,且有较好的预测效能。对于不同ALB和CLcr的多数患者起始负荷剂量400 mg/q12h,iv,3次,维持剂量400~800 mg·d^-1的给药方案可达有效治疗谷浓度。严重感染者需调整负荷剂量至800 mg/q12h,iv,3次,维持剂量400~800 mg·d^-1的给药方案来确保血药浓度达到15 mg·L^-1以上。结论本实验报道了CLcr、ALB对TEC清除率有显著影响,所建模型对TEC在中国成人患者中实现个体化给药具有重要应用价值。     

腹腔镜与开腹全胃切除术治疗Ⅰ期胃癌的近期疗效对比CSCD

目的探讨腹腔镜全胃切除术与传统开腹全胃切除术对Ⅰ期胃癌的近期疗效。方法回顾性分析89例肿瘤位于近端胃的Ⅰ期胃癌,并且行全胃切除术的患者。按照手术方式不同分为腹腔镜组(47例)和开腹组(42例)。通过观察两组患者手术时间、出血量、术后病理相关指标、术后并发症、术后首次进食流质饮食时间及术后住院天数,比较两种手术方式的近期疗效。结果两组患者基线资料对比差异无统计学意义,具有可比性。与开腹组相比,腹腔镜组患者手术时间更长,但术中出血量、术后首次进食流质饮食时间、术后住院天数、术后并发症发生率及并发症等级均低于开腹组(P<0.05)。结论腹腔镜全胃切除术能够在保证Ⅰ期的近端胃癌患者手术安全性的同时,降低患者术中出血量、进食流质饮食时间、术后住院时间及术后并发症。     

Double Forehead Expanded Flaps for Reconstruction of Total Nasal Defect: A Case Report

ObjectiveTo introduce a method for total nasal defect reconstruction with a double forehead expanded flap.Case presentationA 55-year-old man underwent three-stage total nasal reconstruction for a complete nasal defect due to electrical injury. The skin expander was implanted during the 1st stage. Total nasal reconstruction was performed with double expanded forehead flap transfer during the 2nd stage. The unilateral forehead flap was used for lining and the contralateral forehead flap, together with the autologous cartilage and titanium mesh framework, were used for skin replacement. The forehead donor defect was covered with a skin graft. Pedicle division and inset were performed in the 3rd stage.ResultsThere was no flap loss, infection, hematoma, rhinostenosis, or implant exposure over the 2-year follow-up, and satisfactory aesthetic results were achieved.ConclusionThe double forehead expanded flap method is useful for the reconstruction of large composite nasal defects in patients who are not suitable for nasolabial flaps and those who may not tolerate free tissue transfer. The operation has fewer complications and is uncomplicated.     

生长抑素及其类似物联合质子泵抑制剂应用于急性非静脉曲张性上消化道出血的循证分析

目的 系统评价生长抑素及其类似物联合质子泵抑制剂（proton pump inhibitor，PPI）治疗急性非静脉曲张性上消化道出血（acute non-variceal upper gastrointestinal bleeding，ANVUGIB）的有效性和安全性，并分析其用药经济性。方法 采用循证医学方法搜集生长抑素及其类似物联合PPI治疗ANVUGIB的RCT、队列研究进行meta分析，得到相应的有效性及安全性分析结果，并进行成本-效果分析。结果 最终纳入6个RCT均未接受内镜治疗，共610例受试者。Meta分析结果显示，生长抑素及其类似物联合高、中、低剂量PPI治疗在以下方面均优于单用高、中、低剂量PPI治疗，差异有统计学意义，总有效率[OR=3.34，95%CI（2.03，5.47），P<0.000 01]、止血时间[MD=-9.04，95%CI（-11.69，-6.38），P<0.000 01]、输血量[MD=-1.10，95%CI（-1.46，-0.74），P<0.000 01]；在不良反应发生率方面，2组差异无统计学意义[OR=0.49，95%CI（0.11，2.12），P=0.34]。ANVUGIB患者予生长抑素联合高、中、低剂量奥美拉唑与单用高、中、低剂量奥美拉唑进行成本-效果分析，增量成本效果比分别为172.28，217.26，330.37，敏感性分析后显示结果稳定。而接受内镜治疗后应用生长抑素及其类似物联合PPI治疗仅1个队列研究，研究结果显示内镜治疗成功后联合治疗并不优于PPI单药治疗。结论 现有证据表明，生长抑素及其类似物联合PPI治疗未经内镜治疗的ANVUGIB患者为较有效的方案，两者安全性相当、耐受性较好，从药品直接成本考虑，高剂量PPI组联合治疗较中、低剂量PPI组联合治疗更具有成本效果性。而对于经内镜下止血治疗的患者两者疗效相当，可考虑单用PPI。     

富血小板纤维蛋白修复大鼠骨外露创面的实验研究

目的探讨富血小板纤维蛋白(PRF)治疗大鼠骨外露创面的疗效。方法取10~12周龄,250~300 g的雄性SD大鼠24只,应用随机数字表法将其分为3组,每组8只。将所有SD大鼠前头盖骨区域1.5 cm×1.5 cm皮肤全层切除及并去除颅骨表面的骨膜。PRF组创面覆盖PRF;脂肪移植组创面覆盖等量脂肪颗粒;对照组创面覆盖等量生理盐水。分别于第4、7和11天对创面换药。使用Image J软件对骨外露面积进行量化评估。应用HE染色和马松三色染色评估创面新生血管和胶原沉积情况。酶联免疫吸附实验检测创面肉芽组织生长因子水平。组间比较采用随机资料单因素方差分析。结果术后第4天时,PRF组大鼠骨外露比例为57.99%±11.29%;脂肪移植组骨外露比例为45.92%±9.55%;对照组骨外露比例为77.73%±5.57%。第7天时,PRF组大鼠骨外露比例为4.29%±2.28%;脂肪移植组骨外露比例为29.52%±6.33%;对照组骨外露比例为36.90%±8.43%。第11天时,仅PRF组的骨外露创面完全被肉芽组织覆盖,脂肪移植组及对照组均存在不同程度的骨外露,分别为10.15%±1.49%和21.69%±2.40%。PRF组在各时间点创面骨外露面积均显著低于对照组,差异具有统计学意义(P<0.01)。在第7天和第11天时,PRF组的骨外露比例显著低于脂肪移植组,但是在第4天时,脂肪移植组的骨外露比例却低于PRF组,差异均具有统计学意义(P<0.001)。第11天时,HE染色结果显示PRF组的新生微血管密度为(10.37%±0.49%)显著高于脂肪移植组(4.86%±0.83%)和对照组(2.91%±0.31%)(P<0.05),马松三色染色结果显示PRF组的胶原纤维最丰富。酶联免疫吸附实验结果提示第11天时PRF组的生长因子水平均明显升高,与脂肪移植组和对照组比较,差异均具有统计学意义(P<0.05)。结论PRF作为一种取材方便的治疗手段,对修复创面具有良好的疗效,可加快骨外露创面愈合。     

Spectral domain optical coherence tomography findings in myotonic dystrophy

The purpose of the study is to evaluate retinal involvement in a cohort of patients affected by Myotonic Dystrophy type 1 (DM1). Both eyes of 30 patients and one eye of a 31st patient with genetically proven diagnosis of DM1 and both eyes of 20 healthy age- and gender-matched subjects were enrolled. All patients underwent complete ophthalmologic examination including best-corrected visual acuity, intraocular pressure measurement, fundoscopy, fundus autofluorescence, infrared imaging and spectral-domain optical coherence tomography with central macular thickness measurement. DM1 patients showed statistically significant higher central macular thickness values than controls. In the DM1 group, butterfly (14.8%) and reticular (13.1%) pigment abnormalities were found with corresponding drusenoid deposit and focal disruption of photoreceptor and retinal pigment epithelium layers. Compared with the controls, DM1 group had higher prevalence of epiretinal membrane. In the DM1 group, the prevalence of epiretinal membrane and retinal pigment epithelium alterations were directly correlated with age, whereas no correlation was found with disease duration, CTG expansion and MIRS score. In conclusion, in addition to the typical retinal pigment epithelium changes, DM1 is also associated with abnormalities of the vitreoretinal interface, particularly epiretinal membrane, resulting in central macular thickness increase. Both inner and outer retinal alterations were associated with increasing age, suggesting that DM1 may cause a premature aging of the retina.     

Development of Physiologically Based Pharmacokinetic Model for Pregabalin to Predict the Pharmacokinetics in Pediatric Patients with Renal Impairment and Adjust Dosage Regimens: PBPK Model of Pregabalin in Pediatric Patients with Renal Impairment

Pregabalin (PGB) is widely used clinically; however, its pharmacokinetics (PK) has not been studied in pediatric patients with renal impairment (RI). To design optimized PGB regimens for pediatric patients with varying degrees of RI and predict exposure to PGB, physiologically based pharmacokinetic (PBPK) models of PGB were developed and verified, and its disposition was simulated in the healthy population and adults with RI. The simulated results from the PBPK models after single-dose and multi-dose administrations of PGB were consistent with the corresponding observed data based on the fold error values of less than 2. The area under curve ratios were 1.23 ± 0.06, 2.02 ± 0.10, 3.86 ± 0.21, and 9.92 ± 0.79 in pediatric patients with mild, moderate, severe, and end-stage RI, respectively. Based on the predictions for pediatric patients with moderate, severe, and end-stage RI, the maximum dose should not exceed 7, 3.5, and 1.4 mg/kg/day, respectively, among those weighing < 30 kg, and it should not exceed 5, 2.5, and 1 mg/kg/day, respectively, among those weighing > 30 kg. In conclusion, the developed PBPK model is a valuable tool for predicting PGB dosage for pediatric patients with RI.